Predictive models and correlates of protection for testing biodefence vaccines

References

• US FDA HHS. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed. Regist.67, 37988–37998 (2002).
   PubMedGoogle Scholar
• UK Home Office. Animals in Scientific Procedures Division: Examples of Reduction, Refinement and Replacement. The Stationery Office Ltd, London, UK (2005).
   Google Scholar
• Griffiths GD, Hornby RJ, Jagger CP et al. Development of methods to measure humoral immune responses against selected antigens in the common marmoset (Callithrix jacchus) and the effect of pyridostigmine bromide administration. Int. Pharmacol.6, 1755–1764 (2006).
   Google Scholar
• Lever MS, Stagg AJ, Nelson M et al. Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int. J. Exp. Path.89, 171–179 (2008).
   Google Scholar
• van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev. Vaccines7(6), 783–793 (2008).
   PubMed Web of Science ®Google Scholar
• UK Home Office. Guidance on the Operation of the Animals (Scientific Procedures) 1986. Chapter 14. The Stationery Office Ltd, London, UK (2000).
   Google Scholar
• Louhimies S. Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes. ATLA30(2), 217–219 (2002).
   Google Scholar
• Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Research, Commission on Life sciences, National Research Council, DC, USA (1996).
   Google Scholar
• Williamson ED, Flick Smith HC, Waters EL et al. Immunogenicity of the rF1+rV vaccine with the identification of potential immune correlates of protection. Microb. Pathogen42, 11–21 (2007).
   PubMed Web of Science ®Google Scholar
• Albrecht MT, Li J, Williamson ED et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun.75, 5425–5433 (2007).
   PubMed Web of Science ®Google Scholar
• Omland KS, Brys A, Lansky D, Clement K, Lynn F; Participating Laboratories. Interlaboratory comparison of results of an anthrax lethal toxin neutralization. Assay for assessment of functional antibodies in multiple species. Clin. Vaccine Immunol.15(6), 946–953 (2008).
   PubMed Web of Science ®Google Scholar
• Knight SC. Lymphocyte proliferation assays. In: Lymphocytes: a Practical Approach. Klaus GGB (Ed.). IRL Press, Oxford, UK, 189–207 (1987).
   Google Scholar
• Junbao Y, James EA, Huston L, Danke NA, Liu AW, Kwok WW. Multiplex mapping of CD4 T cell epitopes using class II tetramers. Clin. Immunol.120, 21–32 (2006).
   Google Scholar
• von Delwig A, Altmann DM, Charlton FG et al. T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. Ann. Rheum. Dis.66, 599–604 (2007).
   PubMed Web of Science ®Google Scholar
• Musson J, Walker N, von Delvig A, Flick-Smith HC, Williamson ED, Robinson JH. Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J. Biol. Chem.278, 52425–52431 (2003)
   Google Scholar
• Nelson M, Prior JL, Lever MS et al. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J. Med. Microbiol.53, 1177–1182 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrosino DM, Bolon D, Collard H, Van Etten R, Kanchana MV, Finberg RW. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J. Immunol.149, 3978–3983 (1992).
   PubMed Web of Science ®Google Scholar
• Mayers CN, Veall S, Bedford RJ, Holley JL. Anti-immunoglobulin responses to IgG, F(ab’)2, and Fab botulinum antitoxins in mice. Immunopharmacol. Immunotox.25, 397–408 (2003).
   PubMed Web of Science ®Google Scholar
• Griffiths GD, Phillips GJ, Holley J. Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal. Toxicol.19, 873–887 (2007).
   PubMed Web of Science ®Google Scholar
• LeClaire RD, Bavari S. Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob. Agents Chemother.45, 460–463 (2001).
   Google Scholar
• Williamson ED, Flick-Smith HC, LeButt CS et al. Human immune response to a plague vaccine comprising recombinant F1 and rV antigens. Infect. Immun.73, 3598–3608 (2005).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Hodgson I, Walker NJ et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun.73, 5978–5987 (2005).
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest.118, 294–305 (2007).
   Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nature Rev. Micro.5, 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Rees DGC, Gate AJ, Green M et al. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral. Res.67, 87–95 (2005).
   Google Scholar
• Griffin KF, Eyles JE, Spiers I, Alpar HO, Williamson ED. Protection against plague after immunisation with microencapsulated V antigen is reduced by coencapsulation with IFN-γ or IL-4, but not IL-6. Vaccine2, 3650–3657 (2002).
   Google Scholar
• Young JAT, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Ann. Rev. Biochem.76, 243–265 (2007)
   PubMed Web of Science ®Google Scholar
• McEvers K, Elrefaei M, Norris P et al. Modified anthrax fusion proteins deliver HIV antigens through MHC class I and II pathways. Vaccine23, 4128–4135 (2005).
   PubMedGoogle Scholar
• Storni T, Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison J. Immunol.17, 6129–6135 (2004).
   Google Scholar
• Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med.203, 413–424 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EN et al. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun.75, 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30, 23–32 (2008).
   Google Scholar
• Martin JE, Sullivan NJ, Enama ME et al.; VRC 204 Study Team. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol.13, 1267–1277 (2006).
   PubMed Web of Science ®Google Scholar
• Phillpotts RJ. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res.120, 107–112 (2006).
   PubMed Web of Science ®Google Scholar
• Elvin SJ, Bennett AM, Phillpotts RJ. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J. Med. Virol.67, 384–393 (2002).
   PubMed Web of Science ®Google Scholar
• Jones LD, Bennett AM, Moss SR, Gould EA, Phillpotts RJ. Cytotoxic T-cell activity is not detectable in Venezuealn equine encephalitis virus-infected mice. Virus Res.91, 255–259 (2003).
   Google Scholar
• Phillpotts RJ, Jones LD, Lukaszewski RA, Lawrie C, Brooks TJG. Antibody and interleukin-12 treatment in murine models of encephalitogenic flavivirus (St. Louis encephalitis, tick-borne encephalitis) and alphavirus (Venezuelan equine encephalitis) infection. J. Interferon Cytokine Res.23, 47–50 (2003).
   Google Scholar
• Anderson GW, Leary SEC, Williamson ED et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and negative strains of Y. pestis. Infect. Immun.64, 4580–4585 (1996).
   PubMed Web of Science ®Google Scholar
• Miller J, Williamson ED, Lakey JH, Pearce MJ, Jones SM, Titball RW. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol. Med. Micro.21, 213–223 (1998).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Simpson AJ, Titball RW. Chapter 36: Plague. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders & Co., PA, USA, 999–1010 (2006).
   Google Scholar
• Leary SEC, Griffin KF, Galyov EE et al. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb. Pathogen26, 159–169 (1999).
   PubMed Web of Science ®Google Scholar
• Petterson J, Holmstrom A, Hill J et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol. Microbiol.32, 961–976 (1999).
   PubMedGoogle Scholar
• Mueller CA, Broz P, Muller SA et al. The V-antigen of Yersinia forms a distinct structure at the tip of the injectisome needles. Science310, 674–676 (2005).
   PubMed Web of Science ®Google Scholar
• Broz P, Mueller CA, Müller SA et al. Function and molecular architecture of the Yersinia injectisome tip complex. Mol. Microbiol.6, 1311–1320 (2007).
   Google Scholar
• Elvin SJ, Williamson ED. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb. Pathogen37, 177–184 (2004).
   PubMed Web of Science ®Google Scholar
• Parent MA, Berggren KN, Mullarky IK et al.Yersinia pestis V protein epitopes recognized by CD4 T cells. Infect. Immun.73, 2197–2204 (2005).
   PubMedGoogle Scholar
• Parent MA, Berggren KN, Kummer LW et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun.73, 7304–7310 (2005).
   PubMed Web of Science ®Google Scholar
• Brachman PA, Friedlander AM, Grabenstein JD. Chapter 8: Anthrax vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders & Co., PA, USA, 111–126 (2006).
   Google Scholar
• Conlan JW, Oyston PCF. Vaccines against Francisella tularensis. Ann. NY Acad. Sci.1105, 325–350 (2007).
   PubMed Web of Science ®Google Scholar
• Haque A, Easton A, Smith D et al. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J. Infect. Dis.193, 370–379 (2006).
   PubMedGoogle Scholar
• Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J. Infect. Dis.195, 99–107 (2007).
   PubMed Web of Science ®Google Scholar
• Elvin SJ, Healey GD, Westwood A, Eyles JE, Williamson ED. Protection against heterologous B. pseudomallei strains using dendritic cell immunisation. Infect. Immun.74, 1706–1711 (2006).
   PubMed Web of Science ®Google Scholar
• Healey GD, Elvin SJ, Williamson ED. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance post infection. Infect. Immun.73, 5945–5951 (2005).
   PubMed Web of Science ®Google Scholar
• Rowland CA, Lertmemongkolchai G, Bancroft A et al. Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei. Infect. Immun.74, 5333–5340 (2006).
   Google Scholar
• Williamson ED, Vesey PM, Gillhespy KJ et al. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin. Exp. Immunol.116, 107–114 (1999).
   PubMed Web of Science ®Google Scholar
• Jones SM, Griffin KF, Hodgson I, Williamson ED. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine21, 3912–3918 (2003).
   PubMed Web of Science ®Google Scholar
• Amemiya K, Meyers JL, Rogers TE et al. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine27, 2220–2229 (2009).
   PubMed Web of Science ®Google Scholar
• Uddowla S, Freytag LC, Clements JD. Effect of adjuvants and route of immunixations on the immune response ro recombinant plague antigens Vaccine25, 7984–7993 (2007).
   Google Scholar
• Elvin SJ, Williamson ED. The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses. Microb. Pathogen29, 223–230 (2000).
   Google Scholar
• Reithmeier-Rost D, Hill J, Williamson ED et al. The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis. Microbes Dis.9, 997–1002 (2007).
   Google Scholar
• Shim HK, Musson JA, Harper HM et al. Mechanisms of MHC class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunol.119(3), 385–392 (2006).
   PubMedGoogle Scholar
• Ingram RJ, Metan G, Maillere B et al. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J. Immunol.184, 3814–3821 (2010).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Del. Rev.61, 248–255 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Qin L, Self S. Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat. Med.27, 4758–4778 (2008).
   PubMed Web of Science ®Google Scholar
• Qin L, Gilbert PB, Corey L, McElrath J, Self S. A framework for assessing an immunologic correlate of protection in vaccine trials. JID196, 1304–1312 (2007).
   PubMed Web of Science ®Google Scholar
• Kohberger R, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine26, 3516–3521 (2008).
   PubMed Web of Science ®Google Scholar
• Nolan T, Bernstein H, Blatter MM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria–tetanus–acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics118, e602–e609 (2006).
   Google Scholar
• Chan ISF, Li S, Matthews H et al. Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat. Med.21, 3411–3430 (2002).
   PubMed Web of Science ®Google Scholar